You need to enable JavaScript to run this app.
Recon: FDA posts FY 2023 user fees; FDA grants fast-track designation to Lilly’s obesity drug Mounjaro
Recon
Joanne S. Eglovitch
Global
ReconJoanne S. Eglovitch
GlobalReconJoanne S. EglovitchGlobal